Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696258 | 0.81 | CYP2C19 (0.39) | SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL11667062 | 0.68 | — | — | |
| SCHEMBL15662055 | 0.67 | CFTR (0.39) | SLC6A2SLC6A4SLC6A3SMN1; SMN2CYP2C19 | |
| SCHEMBL5031674 | 0.66 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3SMN1; SMN2CYP3A4 | |
| SCHEMBL11131813 | 0.66 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3SMN1; SMN2CYP3A4 | |
| SCHEMBL418658 | 0.66 | CHKA (0.46) | SLC6A2SMN1; SMN2 | |
| SCHEMBL15322506 | 0.64 | SMN1; SMN2 (0.41) | SLC6A2SLC6A4SMN1; SMN2 | |
| SCHEMBL11451095 | 0.64 | TSHR (0.39) | SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL7349683 | 0.63 | CYP3A4 (0.41) | SLC6A2SLC6A4SLC6A3SMN1; SMN2CYP3A4 | |
| SCHEMBL3408213 | 0.63 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | KOHN HAROLD (US) | 2005-06-23 | — | — | US | disclosed |
| US-6875774-B2 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | THE UNIVERSITY OF NORTH CAROLINA (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004013143-A2 | AZA-BRIDGED BICYCLIC AMINE DERIVATIVES FOR USE AS NOVEL CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | NORTH CAROLINA, UNIVERSITY OF, THE | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | SLC6A2 304/4885SLC6A4 475/4885SLC6A3 320/4885 |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | SLC6A2 304/4885SLC6A4 475/4885SLC6A3 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.